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Inroads Into Mechanism
An Overview From the AHA’s Council on Functional Genomics
and Translational Biology
Connie Wu, PhD; Pankaj Arora, MD, FAHA
F or the past decade in human genetics, genome-wideassociation studies (GWAS) have been the backbone for
uncovering novel loci that could underlie a disease or
phenotype of interest. However, the rapid growth in the ﬁeld
of human genetics has been plagued by a bottleneck in
translating these GWAS ﬁndings into the development of
potential therapeutics because of the challenges of identifying
the “causal” variants and elucidating their underlying mech-
anisms of action.1,2 Recent advances in epigenomics (eg, the
Roadmap Epigenomics Project3,4) and genome editing (eg, the
CRISPR/Cas9 technology5) have greatly facilitated our armory
to dissect causality from GWAS data, equipping us with a
range of resources that are necessary to understand the
complex underpinnings of how speciﬁc variants can con-
tribute to disease pathophysiology.
In the study by Claussnitzer et al6 published in the New
England Journal of Medicine, the authors illustrate how
researchers can use an integrative approach, taking advan-
tage of novel epigenetic tools and genome editing techniques,
as well as traditional cellular and mouse models, to identify a
potential causal mechanism for the association of a noncod-
ing variant in the fat mass and obesity–associated (FTO) locus
with obesity (Figure).
The initial reports demonstrating the association of the FTO
locus with body mass index (BMI) and the risk of obesity were
published in 2007 by Frayling et al7 and Dina et al.8 These
studies revealed that the strongest genome-wide association
signal is located in a 47-kb region of the ﬁrst 2 introns of the
FTO gene.7,8 The large number of genetic variants in linkage
disequilibrium in this region (89 in total), as well as the lack of
protein-altering variants, has made it challenging to pinpoint
the “causal” variant and its underlying mechanism of action.
Now, nearly a decade later, in a tour de force series of
experiments, Claussnitzer et al6 identify a causal variant
(rs1421085) in intron 1 of the FTO gene and present evidence
that this variant modulates the binding of a transcriptional
repressor, which plays a role in regulating the expression of 2
homeobox regulatory genes that are involved in the develop-
ment and function of preadipocytes.
Using recently available chromatin state annotation data
from the Roadmap Epigenomics Project,3,4 Claussnitzer et al6
found that intron 1 of the FTO gene contains a 12.8-kb-long
enhancer that is most active in mesenchymal adipocyte
progenitors. Subsequent enhancer luciferase reporter assays
revealed a difference in the activity of this enhancer
depending on the presence or absence of the FTO risk (ie,
obesity-associated) haplotype, with the risk haplotype having
2.4 times higher enhancer activity than the nonrisk haplotype
in human adipocytes. These results suggested that the FTO
variants could be controlling enhancer activity. In an expres-
sion quantitative trait locus analysis, the authors observed
that the mRNA levels of IRX3 and IRX5 were higher in adipose
progenitor cells isolated from carriers of the FTO risk
haplotype compared with carriers of the nonrisk haplotype.
In addition, by using the chromosome conformation capture
technique, the authors found that both IRX3 and IRX5 can
directly interact with the FTO locus via long-range (1.2-Mb)
chromatin interactions. These ﬁndings suggest that IRX3 and
IRX5 could be putative target genes of the FTO-associated
enhancer.
Next, the authors examined the effects of knocking down
or overexpressing IRX3 and IRX5 in preadipocytes isolated
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from both carriers of the FTO risk haplotype and carriers of
the nonrisk haplotype. They found that silent interfering (si)
RNA-mediated knockdown of either IRX3 or IRX5 in
preadipocytes from the risk haplotype carriers restored
oxygen consumption and thermogenesis response to levels
seen in the nonrisk haplotype carriers. In contrast, doxycy-
cline-mediated overexpression of either IRX3 or IRX5 in
preadipocytes from nonrisk haplotype carriers reduced mito-
chondrial function and thermogenesis response to levels seen
in risk haplotype carriers. The authors then investigated the
effects of the repression of Irx3 in a mouse model, which
expresses a dominant-negative form of Irx3 speciﬁcally in
adipose tissue (aP2-Irx3DN mice). These mice were found to
exhibit a smaller body size and reduced body weight, fat mass,
and adipocyte size compared with control mice. Moreover, the
aP2-Irx3DN mice had increased energy expenditure and
oxygen consumption and were resistant to weight gain when
fed a high-fat diet. All of these features are in line with an
antiobesity phenotype and provide support for the human
observations. Taken together, these results suggest that IRX3
and IRX5 may regulate obesity-associated phenotypes in
preadipocytes via an FTO-mediated mechanism.
To attempt to identify the causal variant in the FTO locus,
the authors used the phylogenetic module complexity analysis
(PMCA),9 which is a tool that was developed in their
laboratory to analyze “the evolutionary conservation of cis-
regulatory modules across related species.”6 Based on this
analysis, the authors honed in on the rs1421085 (T/C)
variant, which was reported to have the highest PMCA score.
This variant was also found to lie in a conserved binding motif
for the AT-rich interaction domain (ARID) family of transcrip-
tional regulators. By conducting electrophoretic mobility shift
assays, the authors showed that the risk allele (C) of
rs1421085 disrupts the binding of the ARID5B transcriptional
repressor, which is highly expressed in adipose tissue and
adipocytes, resulting in increased enhancer activity at the FTO
locus. To study the potential role of ARID5B in regulating the
expression of IRX3 and IRX5, the authors examined the effects
of knocking down or overexpressing ARID5B in preadipocytes
isolated from carriers of the FTO risk haplotype and carriers of
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Figure. Integrative approach for deciphering the mechanistic basis of a disease-associated noncoding
genetic variant. A combination of genomic/epigenomic data, molecular tools, and cellular and animal
models can be used to enable the identiﬁcation of a causal variant in a disease-associated locus and its
potential mechanism of action in a relevant tissue/cell type. Speciﬁc examples of the types of data, tools,
and models used in Claussnitzer et al6 are listed in the ﬁgure. Using this integrative approach, Claussnitzer
et al6 established a putative causal variant (rs1421085) in the FTO obesity-associated locus and its
potential underlying mechanism of action in adipose progenitor cells. Speciﬁcally, the rs1421085 risk allele
disrupts the binding of ARID5B to a repressor motif in intron 1 of the FTO gene, resulting in increased
enhancer activity and increased expression levels of target genes IRX3 and IRX5, which subsequently leads
to obesity-associated phenotypes.
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the nonrisk haplotype. They found that siRNA-mediated
knockdown of ARID5B in preadipocytes from nonrisk haplo-
type carriers not only increased the IRX3 and IRX5 mRNA
levels to levels seen in risk haplotype carriers but also
reduced basal oxygen consumption and lipolysis and altered
expression patterns from mitochondrial to lipid markers.
Conversely, doxycycline-mediated overexpression of ARID5B
in preadipocytes from nonrisk haplotype carriers resulted in a
reduction in the mRNA levels of IRX3 and IRX5. Taken
together, these ﬁndings support their model in which the
rs1421085 risk allele disrupts the ARID5B binding motif,
preventing ARID5B from binding to the DNA and leading to
increased enhancer activity and subsequent increases in the
expression levels of the target genes IRX3 and IRX5.
In an elegant series of genome editing experiments, the
authors used CRISPR/Cas9 technology to examine the effects
of altering the predicted causal variant rs1421085, either
changing the rs1421085 T allele to the C allele in preadipo-
cytes from nonrisk haplotype carriers (which would be
expected to disrupt the ARID5B motif) or changing the
rs1421085 C allele to the T allele in preadipocytes from risk
haplotype carriers (which would be expected to rescue the
disrupted ARID5B motif). They demonstrated that genome
editing of the T allele to the C allele increased the mRNA levels
of IRX3 and IRX5 in preadipocytes from the nonrisk carriers
and, interestingly, reediting the C allele back to the T allele
restored low IRX3 and IRX5 mRNA levels in the preadipocytes.
On the other hand, genome editing of the C allele to the T allele
decreased the mRNA levels of IRX3 and IRX5 in preadipocytes
from the risk carriers, and this decrease was not observed
when ARID5B was knocked down. These ﬁndings suggest that
the function of the rs1421085 variant is mediated by ARID5B,
which regulates the expression of IRX3 and IRX5 in
preadipocytes. Moreover, the authors found that the C-to-T
genome editing in preadipocytes from the risk carriers
increased the mRNA levels of a number of thermogenesis
regulators and mitochondrial markers, decreased the mRNA
levels of lipid storage and lipolytic markers, and increased
basal metabolic rate, oxygen consumption, and thermogene-
sis. Taken together, these results provide evidence that
rs1421085 could be the long-sought-after causal variant
underlying the association between the FTO locus and obesity.
The study by Claussnitzer et al6 has uncovered a potential
causal mechanism by which the rs1421085 variant in the FTO
gene acts to exert its effect on obesity, advancing our
understanding of this prominent obesity-associated locus. The
fact that rs1421085 is an intronic variant highlights the
importance of studying noncoding variants in our systematic
efforts to follow GWAS signals to ascertain the “causal”
variant underlying the disease of interest. In fact, it has been
reported that the majority of the variants identiﬁed by GWAS
are located in noncoding regions of the genome.10 Although
noncoding DNA sequences do not encode proteins, one
should be cognizant that variants in noncoding DNA regions
can still be functional by affecting transcriptional regulation,
posttranscriptional regulation,11 or epigenetic regulation as
illustrated by Claussnitzer et al.6 The rs1421085 risk allele
disrupts the binding of the transcriptional repressor, ARID5B,
to an enhancer sequence in the DNA, leading to increased
activity of the enhancer and subsequent upregulation of the
expression levels of the downstream target genes IRX3 and
IRX5. Although the molecular mechanisms by which IRX3 and
IRX5 affect mitochondrial oxygen consumption and thermo-
genesis remain to be elucidated, the discovery of the ARID5B-
FTO-IRX3/IRX5 regulatory axis provides an exciting opportu-
nity to stimulate the development of innovative strategies that
enhance the thermogenic properties of adipocytes as an
approach to combat obesity. In addition to considering
strategies to induce known regulators of thermogenesis, such
as UCP1 and PGC1A, one might envisage discovering and
developing drugs that would therapeutically perturb IRX3/
IRX5 or other targets in the ARID5B-FTO-IRX3/IRX5 pathway
to help promote the browning of adipocytes and increase
thermogenesis and energy expenditure. Because it is likely
that these targets play a role in other biological processes, a
major challenge in therapeutic development will be to
manipulate these targets in a speciﬁc way to avoid potential
deleterious off-target effects in nonadipose tissue. In this
regard, it may be informative to investigate whether there are
other disease phenotypes or traits, besides obesity, that are
associated with the rs1421085 genetic variant, as such
knowledge could be used to gain a more comprehensive
understanding of the potential untoward consequences, if
any, of modulating the ARID5B-FTO-IRX3/IRX5 pathway.
Last but not least, the study by Claussnitzer et al6 offers a
roadmap for interpreting GWAS ﬁndings. By starting with a
GWAS signal, researchers can consider using a combination
of epigenomic, phylogenetic, and expression quantitative trait
locus analyses to uncover the pathogenesis of the disease-
associated locus in the relevant tissue/cell type. An array of
cutting-edge molecular tools and state-of-the-art technologies
could then be used to enable the identiﬁcation of novel
targets and pathways through which the variant acts to exert
its effect on the disease phenotype. As demonstrated by
Claussnitzer et al6 in their discovery of the ARID5B-FTO-
IRX3/IRX5 regulatory pathway, the advent of the chromo-
some conformation capture technique has facilitated our
ability to identify “causal” genes that are not necessarily in
the vicinity of the genetic variant in the DNA sequence but
are, in fact, large genomic distances away. Moreover,
Claussnitzer et al6 showed that CRISPR/Cas9 genome editing
is a convenient and powerful tool to dissect causality of a
genetic variant. The CRISPR/Cas9 technology allows
researchers to introduce the risk allele of the variant in a
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speciﬁc cell type of interest, evaluate the effect of that allele
on cellular function/phenotype, and test whether correcting
the allele back to the nonrisk allele would rescue the cellular
function/phenotype. These single-nucleotide editing experi-
ments can provide compelling evidence that the risk allele is
sufﬁcient to bring about the disease phenotype. Overall, the
study by Claussnitzer et al6 is a great example of how
researchers can capitalize on the genomic and technological
advances of the past decade to gain mechanistic insights into
observed genetic associations with human diseases.
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